​
  Institute for Cardiovascular Imaging Goethe University Frankfurt
  • Home
    • Team
    • Eike Nagel
    • Valentina Puntmann
    • Infrastructure
  • Research&Development
    • IMPReSSION Study
    • Impression COVID-19 Study
    • T1 Outcome Study
    • MR-INFORM
    • Decipher- HFpEF
    • Speed and Standardization
    • Patients in Research
    • Distr@l
  • MYOFLAME-19
  • Upcoming Courses
    • CMR in Everyday Practice
    • T1 and T2 Mapping Wksh
  • In the media
    • COVID19 FAQ
  • Legal
    • Impressum
    • Datenschutz
    • Legal Notice
    • Privacy policy
Picture
Abstract. Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen. 

Main Manuscript

Table i - Authors log
Tables 3c-I T1 mapping
Table ii Evidence Rank
Tables 3C-II T2 mapping
Tables 3a Ventricular volumes
Tables 3C-III T2* mapping
Tables 3B-I LGE
Tables 3D - Myocardial Perfusion
Tables 3B-ii T2W Imaging
Tables 4 Vascular Imaging

Link to JCMR Website
Powered by Create your own unique website with customizable templates.